课题基金 / 基金详情

Preclinical Evaluation Of Neutralizing Antibodies Elicited by HIV-1 Immunogens

Preclinical Evaluation Of Neutralizing Antibodies Elicited by HIV-1 Immunogens
HIV-1 免疫原引发的中和抗体的临床前评估
批准号：
7732735
负责人：
John R Mascola
金额：
$32.02万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/7732735
关键词：
AdenovirusesAnimalsAntibodiesAntibody FormationAntigensDNAEvaluationHIV-1ImmunizationLeadMacaca mulattaProteinsRecombinantsTestingTreatment ProtocolsVaccinesVirusdesignneutralizing antibodynovelnovel vaccinesplasmid DNApre-clinical

项目摘要

项目成果

John R Mascola的其他基金

相似基金

相关文献

中文摘要
翻译
本研究考察了小动物和恒河猴在不同免疫方案后中和抗体（NAb）反应的广度和程度。使用标准化的多层参考Env假病毒面板进行NAb评估，我们发现蛋白质免疫和DNA引物（rAd增强免疫）都可以产生高抗体滴度。原代病毒中和的效力和广度仍然有限。免疫原设计的持续优化将导致新疫苗的测试。
英文摘要
The present studies examine the breadth and magnitude of neutralizing antibody (NAb) responses in small animals and rhesus monkeys after various immunization regimens. Using a standardized multi-tier panel of reference Env pseudoviruses for NAb assessment, we show that both protein immunization, and DNA prime, rAd boost immunization, can generate high antibody titers. The potency and breadth of neutralization of primary viruses is still limited. Ongoing optimization of immunogen design will lead to new vaccines to test.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
PASSIVE ANTIBODY PROTECTION IN SHIV CHALLENGE MODEL
PASSIVE ANTIBODY PROTECTION IN SHIV CHALLENGE MODEL
PASSIVE ANTIBODY PROTECTION IN SHIV CHALLENGE MODEL
Immunogenicity Studies of HIV-1 immunogens
海外基金